Krystal Biotech, Inc. (KRYS)
Krystal Biotech, Inc. (KRYS) from its SEC filings: 2025 revenue $389.1 million (+34% vs the year before), net margin 53%, free cash flow $188.9 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $389.1 million |
| Revenue growth | +34% |
| Net income | $204.8 million |
| Net margin | 52.6% |
| Free cash flow | $188.9 million |
| Diluted EPS | $6.84 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +24% |
| Cash | $427.7 million |
| Long-term debt | $4.3 million |
| Share count, 1 year | +2% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.